The splicing factor kinase SRPK1 is a therapeutic target for Peripheral Vascular Disease
Sohni Ria Bhalla, Mussarat Wahid, Jason O. Amartey, Amira Zawia, Federica Riu, Yizhuo Gao, Jyoti Agrawal, Amy P. Lynch, Maria J. C. Machado, Tom Hawtrey, Ryosuke Kikuchi, Kathryn R. Green, Lydia Teboul, Claire Allen, Zoe Blackley, , David O. Bates
This paper shows that inhibiting SRPK1 in monocytes promotes angiogenesis by altering VEGF splicing from anti-angiogenic VEGF-A165b to pro-angiogenic VEGF-A165a in both human and mouse models of peripheral arterial disease.
bioRxiv · Apr 17, 2024Physiology